Life sciences · Journal article

Fecal Zonulin as a Potential Biomarker of Intestinal Barrier Dysfunction in Obesity: Molecular Mechanisms, Clinical Validation, and Methodological Challenges - Review of Literature

Quality in Sport · August 13, 2026

Important Confirmatory Evidence Why this matters to you Expert discussion

Reinforces what was already believed, rather than introducing something new.

AI Summary

This narrative literature review confirms that fecal zonulin is elevated in obesity and correlates with intestinal barrier dysfunction and systemic inflammation, and that weight loss improves barrier integrity. The authors acknowledge that while zonulin is a validated non-invasive biomarker, its routine clinical application remains limited by lack of standardization and further validation.

What was studied

Narrative literature review. Studies and literature on zonulin, intestinal permeability, obesity, and related biomarkers; no specific patient cohort enrolled.

Key findings

Higher fecal zonulin concentrations were consistently associated with increased body mass index (BMI) Impaired intestinal barrier integrity is directly related to systemic low-grade inflammation in obesity Weight loss improved intestinal epithelial integrity and was accompanied by favorable changes in gut microbiota composition

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Clinicians should recognize fecal zonulin as a validated non-invasive biomarker for intestinal barrier dysfunction in obesity, but recognize that standardization and further validation are required before routine clinical application is recommended.

Plain-language summary

A literature review synthesizing established mechanistic links between obesity, zonulin, and intestinal barrier dysfunction, confirming known pathophysiology without new primary data or clinical trials.

Study design

As stated by the source record.

MethodsPubMed/MEDLINE and Google Scholar databases were searched for publications addressing zonulin, intestinal permeability, obesity, fecal biomarkers, epithelial transport mechanisms, ELISA assay specificity, and clinical correlations. No structured selection criteria, study quality assessment tool, or data extraction protocol is described.

DesignNarrative literature review

PopulationStudies and literature on zonulin, intestinal permeability, obesity, and related biomarkers; no specific patient cohort enrolled

Clinical bottom line

Caveats

No numerical effect sizes, confidence intervals, or p-values provided for reported associations
Individual study sample sizes, design types, and quality assessment not reported
Specific methodological challenges and standardization gaps identified in title are discussed conceptually but not quantified
No meta-analysis or systematic quantification of consistency across reviewed studies

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Literature review only; no primary data collection or novel experimental design.

Directness

moderate

Reviews clinical studies on zonulin and BMI, intestinal permeability and inflammation, weight loss effects.

Consistency

moderate

Reports consistent associations across reviewed studies but does not quantify heterogeneity or conflicting findings.

Risk of bias

insufficient

No systematic risk assessment or meta-analysis methodology reported; selection criteria for reviewed studies not stated.

Sample adequacy

insufficient

Aggregated review without reporting total sample size, individual study N, or power calculations.

What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Introduction: Intestinal permeability is a tightly regulated physiological process that enables the transport of nutrients and ions while preventing the passage of harmful luminal antigens. The term "leaky gut" is often misused in pseudoscientific contexts, despite the existence of well-established physiological mechanisms regulating epithelial barrier function. In obesity, chronic low-grade inflammation and gut dysbiosis stimulate the secretion of zonulin, a physiological modulator of tight junctions (TJs). Increased zonulin levels promote pathological disruption of the leak pathway, contributing to systemic low-grade inflammation. Assessment of intestinal barrier integrity may have clinical value in evaluating metabolic risk and monitoring subclinical inflammation. Methods: A literature search was conducted using the PubMed/MEDLINE and Google Scholar databases. Publications addressing zonulin, intestinal permeability, obesity, fecal biomarkers, epithelial transport mechanisms, ELISA assay specificity, and clinical correlations were reviewed. Results: Higher fecal zonulin concentrations were consistently associated with increased body mass index (BMI). Clinical studies demonstrated a direct relationship between impaired intestinal barrier integrity and systemic low-grade inflammation. Weight loss improved intestinal epithelial integrity and was accompanied by favorable changes in gut microbiota composition. Conclusions: Increased intestinal permeability in obesity is a pathological consequence of tight junction dysfunction. Fecal zonulin is a validated, non-invasive biomarker of intestinal barrier impairment and may be useful for monitoring the effectiveness of metabolic interventions. However, its routine clinical application remains limited due to the need for further standardization and validation.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Weronika ZającKamil KuneckiMiłosz PlichtaJan WandzelZofia WandzelAleksander Urbaś